

Corporate Profile

April 2026

Allmed at a Glance

Innovation in a truly global company

Allmed Group is a globally integrated, end-to-end provider of haemodialysis products, headquartered in the United Kingdom with direct operations across Germany, Egypt and Brazil.

With a workforce of 1,500 employees and products distributed in over 50 countries, Allmed is the only company in the world to successfully steam autoclave Polysulfone membranes, and holds the broadest portfolio of dialyzers available on the global market

30+

YEARS IN OPERATION

1,500

EMPLOYEES WORLDWIDE

50+

COUNTRIES SERVED

\$75M

2026 REVENUE EXPECTATION – CAGR: > 6%

PATENTS

MULTIPLE ACTIVE PATENTS

>100M

TREATMENTS SINCE INCEPTION

FULL MDR CE MARK (EU) ACROSS ENTIRE PORTFOLIO –
1ST WW TO ACHIEVE THIS IN DIALYSIS (BSI)

Global Institutional Investors in Allmed




A SOLID & PRESTIGIOUS FINANCING ENABLES
ALLMED TO INVEST IN THE FUTURE

Global Presence + Operations

Direct operations across three continents

Allmed operates design, development, manufacturing and distribution facilities across four strategic locations, supported by a deeply established distribution network spanning 50+ countries.



GERMAN ENGINEERING KNOW-HOW, QUALITY
& COMPETITIVE-COST MASS PRODUCTION IN EGYPT

Complete Dialysis Treatment Package

One-stop-shop for the complete haemodialysis treatment cycle

Allmed is uniquely positioned as a single-source supplier for every medical device and pharmaceutical required in a haemodialysis session, reducing procurement complexity and ensuring compatibility.



DIALYZERS

- Widest Range:** 0;042–2.6 m² surface area
- Membranes:** Polysulfone & PES
- Flux:** Low, Mid & High
- Sterilization:** Steam, EO & Gamma



DIALYSATE

- BIOCARB-G:** Bicarbonate (Patented design): 650/750 g
- Concentrates:** Acidic 5–20L, with/without glucose



BLOODLINES & NEEDLES

- Coverage:** Full range for major platforms
- Safety:** DEHP-free options
- Access:** High-quality Fistula Needles



ULTRAFILTERS & ACCESSORIES

- Ultrafilters:** Endotoxin retention
- Disinfection:** DialClean cartridges
- Others:** CRRT filters, heparin & infusion solutions

VERTICAL INTEGRATION & THE WORLD’S MOST COMPLETE DIALYZER PORTFOLIO

Dialyzers—World’s Most Complete Portfolio

From neonatal to high-volume

Allmed manufactures the widest range of dialyzers available on the global market today. This breadth of range, combined with dual membrane technology and pioneering steam sterilization, sets Allmed apart from all competitors.



Dual Membranes

Only major player to offer both Polysulfone (PS) and PolyEtherSulfone (PES).

Flux Options

Complete range available in Low, Medium, and High Flux variants.

Sterilisation Is Differentiation


Steam Autoclave & Gamma options available.

Widest Surface Area Range

From 0.042 m² (Neonatal) to 2,6 m² (largest surface in market – MID CUTOFF REMOVAL in HDF).

VERTICAL INTEGRATION & THE WORLD’S MOST COMPLETE DIALYZER PORTFOLIO

Global Allmed Dialyzer Range



THE MOST COMPLETE DIALYZER PORTFOLIO
WORLDWIDE (53 REFERENCES)

Terminal Autoclave Steam Sterilization

The gold standard in biocompatibility & reduced toxicity

Allmed is the only major manufacturer to successfully apply terminal steam sterilization to Polysulfone dialyzers, eliminating the risks associated with chemical residues.



Zero Chemical Residues


Avoids the potential toxicity of EtO (Ethylene Oxide) and Gamma radiation byproducts.

Reduced Inflammation

Proven to lower inflammatory markers (CRP, IL-6) in patients compared to other sterilization methods.

Environmentally Friendly

The process uses only purified water and heat, releasing no ozone or harmful emissions.



Pure Water

System is primed with medical-grade purified water.

121°C Heat

Subjected to 121°C for 15 minutes (Autoclave Cycle).

121°C Heat

Subjected to 121°C for 15 minutes (Autoclave Cycle).

“The safest choice for patient and planet.”

Every dialysis session is an exposure—sterilisation method cannot be an afterthought

A standard haemodialysis patient undergoes treatment three times per week. The sterilisation method directly determines what chemical residues and biological contaminants the patient’s blood encounters during each of these 156 annual sessions.


156

Dialyzer Exposures
Per Year



Clearance Performance

Removal of Uremic Toxins



Biocompatibility

Minimising blood-surface contact effects



Material Toxicity

Safety constituent materials



SUMMARY

Steam sterilisation delivers several evidence-based patient safety advantages

A standard haemodialysis patient undergoes treatment three times per week. The sterilisation method directly determines what chemical residues and biological contaminants the patient’s blood encounters during each of these 156 annual sessions.

WHY

Steam sterilisation provokes less structural polymer degradation (as heat sterilisation is chemically inert).

HOW		ADVANTAGE	CLINICAL IMPACT	REMEDIES
		1. Superior endothelial cell viability	CARDIOVASCULAR	↓ atherosclerosis/CV events ↓ transplant rejection
		2. Lower oxidative stress & DNA damage; No MDA release	REDUCED CANCER RISK	↓ anaemia ↑ immune function ↓ exposure
		3. Lower PVP elution (>80 % less) in blood	PVP STORAGE DISEASE	↓ bone destruction ↓ anaphylaxis ↓ bone marrow
		4. No thrombocytopenia risk	HAEMOSTASIS	↓ bleeding complications

WHAT

Reduced HEPARIN INTAKE:
Thanks to a reduced platelet activation & lower PVP elution, dialyzers are more hemocompatible & require less/no heparin intake.

GREEN DIALYSIS:
Steam sterilisation participates in ‘green dialysis’ as no ozone emission (Staff safety, environmental compliance, sustainability)

Independent studies regarding steam-sterilisation

References:

1. Müller T, Seitz M, Eckle I, Lange H, Kolb G. Biocompatibility Differences with Respect to the Dialyzer Sterilization Method. Nephron. 1998; 78:139-142. <https://doi.org/10.1159/000044901>
1. Aucella F, Vigilante M, Grandone E, Colaizzo D, Margaglione M, Modoni S, Orlandini G, Stallone C. Reduction of Mononuclear Cytokine Production in Hemodialysis Patients Treated with Steam-Sterilized Low-Flux Polysulphone Membranes. The International Journal of Artificial Organs. 1998; 21:210-215. <https://doi.org/10.1177/039139889802100407>
1. Aucella F, Vigilante M, Gatta G, Grandone E, Colaizzo D, Margaglione M, Modoni S, Stallone C. Effects of ethylene oxide and steam sterilization on dialysis-induced cytokine release by cuprophan membrane. Artificial Organs. 2002; 26(6):543-5. https://doi.org/10.1046/j.1525-1594.2002.06886_1.x
1. Golli-Bennour E, Zaied C, Bouaziz C, Guedri Y, Achour A, Abid S, Bacha H. Do Sterilization Processes Really Make Difference in Dialysis-Induced Genotoxicity? World Journal of Nephrology and Urology. 2017; 6:14-17. <https://doi.org/10.14740/wjnu296e>
1. Golli-Bennour E, Kouidhi B, Dey M, Younes R, Bouaziz C, Zaied C, Bacha H, Achour A. Cytotoxic effects exerted by polyarylsulfone dialyser membranes depend on different sterilization processes. International Urology and Nephrology. 2011; 43:483-490. <https://doi.org/10.1007/s11255-009-9653-7>
1. Zawada A, Melchior P, Erlenkötter A, Delinski D, Stauss-Grabo M, Kennedy J. Polyvinylpyrrolidone in hemodialysis membranes: Impact on platelet loss during hemodialysis. Hemodialysis International. 2021; 25:498-506. <https://doi.org/10.1111/hdi.12939>
1. Krüger T, Dellanna F, Kleophas W, Flader O, McClure C, Caiazzo M, Manfredini S. Safety and performance of the Clearum™ high flux hemodialyzer. Artificial Organs. 2023; <https://doi.org/10.1111/aor.14676>
1. Forsberg U, Jonsson P, Stegmayr C, Jonsson F, Nilsson B, Ekdahl K N, Stegmayr B. A high blood level in the venous chamber and a wet-stored dialyzer help to reduce exposure for microemboli during hemodialysis. Hemodialysis International. 2013; 17. <https://doi.org/10.1111/hdi.12052>
1. Said N, Lau W, Ho Y, Lim S, Abidin M N Z, Ismail A. A Review of Commercial Developments and Recent Laboratory Research of Dialyzers and Membranes for Hemodialysis Application. Membranes. 2021; 11. <https://doi.org/10.3390/membranes11100767>

Bicarbonate Cartridges & BiBags

Patented designs and sustainable manufacturing

Allmed brings genuine innovation to the bicarbonate segment—a category often treated as a commodity. Our patented designs improve transportability and significantly reduce the carbon footprint.



Green Product Award

2025 Finalist — Project DeCarb

Recognized for the novel shock-absorber design in the BIOCARB-G cartridge, reducing breakage and environmental impact.



BIOCARB-G (BiCart) Features a design-enabled shock absorber. Judged as “novel & inventive” by the patent office. 650g/750g	PATENTED
5008 BiBag (650g) 500,000+ units sold. Uses medical-grade powder from Solvay and Humens (NovaCarb).	RELEASED 2025
5008 BiBag (900g) Expanding the range to support higher dose treatments.	COMING 2026
4008 BiBag Legacy product. Allmed was a pioneer in this segment, selling millions of units globally.	RETIRED

Blood Tubing Sets

Market leadership through innovation

Allmed has one of the broadest blood tubing set portfolios in the world, covering all major haemodialysis machine platforms. The company is known as the first to unlock captive systems—either through identical versions or patented engineering workarounds.



Quality Differentiators

- 100% EU Components/Raw Mat.
- Special-grade High Performance Pump Segment
- Clean Room Inspection
- 100% Leak Tested



BBraun Dialog + Full coverage of Dialog & Dialog+ families	Nipro Surdial X First to supply identical version; patented workaround for patent-covered territories
Baxter/Gambro Phoenix and ARTIS First to release identical version; cassette-based tubing sets available	Nikkiso DBB Series Full DBB family coverage; workarounds secured for EXA patented components
Fresenius 4008 Major supplier in EMEA and LATAM regions	UPCOMING Fresenius 5008 (Launch 2026) Will make Allmed the only non-FMC supplier of the full 5008 consumable suite

Tomorrow

- New POLYPURE® XL and VAPURE® XL being released in 12 months offering the largest Dialyzers on the world market (today BIOREMA® 26H)
- POLYPURE® RE/VAPURE® RE (Renewable) released Q4-2026 which will be the first ever climate neutral dialyzer when it comes to the Plastic parts (housing + headers)
- Recycling the dialyzer after use into car headlamps (UK trial, Covestro press release) will roll out after that to France and one other European market
- New Paediatric Dialyzers (0.6-0.8m²) will be released Q1-2027
- Release of full range of Baxter and Fresenius machine Ultrafilters (Endotoxin Filters) by Q4-2026
- 900g DiaCardS to be released in Q3-2026
- Full range of POLYPURE ACUTE products already exists & will be completed (ie: for Nikkiso AQUARIUS)



Why Allmed

Five pillars of competitive advantage

01

Broadest Range & Quality

Widest dialyzer portfolio globally. Only player with both PS & PES membranes.



02

Biocompatibility

Steam-sterilised dialyzers with documented biocompatibility advantages.



03

Innovation & IP

Multiple patents. First to unlock every major captive platform as well as steam sterilisation for dialysers or the Biocarb design.



04

Human, Flexible, Reactive

Most responsive company in the market to customer and patient requirements. Agile, multi-site operations enabling rapid adaptation.



05

Sustainability

Ozone-free sterilization. Eco-designed BiCart (GPA Finalist).



Allmed references

A truly global player

STRATEGIC PARTNERSHIPS:

Oxford University Hospitals

“Oxford University Hospitals uses exclusively Allmed products for all in-centre and home haemodialysis patients, delivering over 70,000 treatments per year.”



STRATEGIC PARTNERSHIPS:

Hemotech

“Hemotech France and a major German dialysis actor buy more than 1,5 million dialyzers from Allmed every year.”



STRATEGIC PARTNERSHIPS:

Allmed Brazil

“Allmed Brazil (ABR) ensures about 20% of all treatments in the country.”





Thank you